Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Wolf, Claudia [VerfasserIn]   i
 Herold-Mende, Christel [VerfasserIn]   i
 Schirrmacher, Volker [VerfasserIn]   i
Titel:An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules
Verf.angabe:Claudia Haas, Christel Herold-Mende, Roswitha Gerhards, and Volker Schirrmacher
Umfang:9 S.
Fussnoten:Gesehen am 20.02.2019
Titel Quelle:Enthalten in: Cancer gene therapy
Jahr Quelle:1999
Band/Heft Quelle:6(1999), 3, S. 254-262
ISSN Quelle:1476-5500
Abstract:A new, generally applicable procedure is described for the introduction of defined costimulatory molecules into human cancer cells to increase their T-cell stimulatory capacity. The procedure involves infection with Newcastle disease virus to mediate the cell surface binding of costimulatory molecules (e.g., specially designed bispecific antibodies (bsAb)). The modification is independent of tumor cell proliferation and laborious recombinant gene technology and can be applied directly to freshly isolated and γ-irradiated patient-derived tumor cells as an autologous cancer vaccine. Following the infection of tumor cells with a nonvirulent strain of Newcastle disease virus, the cells are washed and then further modified by coincubation with bsAbs, which attach with one arm to the viral hemagglutinin-neuraminidase (HN) molecule on the infected tumor cells. The second specificity of one bsAb (bs HN × CD28) is directed against CD28 to augment antitumor T-cell responses by selectively channeling positive costimulatory signals via the CD28 pathway. A second bsAb (bs HN × CD3) was produced to deliver T-cell receptor-mediated signals either alone (bsCD3 vaccine) or in combination with anti-CD28 (bsCD3 vaccine plus bsCD28 vaccine). In human T-cell stimulation studies in vitro, the bsCD28 vaccine caused an up-regulation of early (CD69) and late (CD25) T-cell activation markers on CD4 and CD8 T lymphocytes from either normal healthy donors or cancer patients (autologous system) and induced tumor cytostasis in nonmodified bystander tumor cells. In addition, in combination with the bsCD3 vaccine, augmented antitumor cytotoxicity and T-cell proliferative responses were observed. This tumor vaccine modification procedure is highly specific, quick, economic, and has a broad range of clinical applications.
DOI:doi:10.1038/sj.cgt.7700048
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Verlag: http://dx.doi.org/10.1038/sj.cgt.7700048
 Verlag: https://www.nature.com/articles/7700048
 DOI: https://doi.org/10.1038/sj.cgt.7700048
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1587841347
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68360547   QR-Code
zum Seitenanfang